19 Feb
European Cancer Conference and American College of Gastroenterology: American College of Gastroenterology
Crohn’s Disease with Fistula
Adalimumab (Humira, Abbott), a fully human monoclonal antibody that targets tumor necrosis factor (TNF), has been found efficacious for inducing and maintaining remission in patients with Crohn’s disease (CD). According to data presented at the meeting, adalimumab offers sustained responses for the 20% to 30% of patients whose course is complicated by [...]